Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

Neuraxis, Inc.’s NRXS investors have been gaining from the stock over the past year. Shares of the Carmel, IN-based medical technology company gained 136.6% in the past year against the industry’s 12.2% decline. It has also outperformed the sector and the S&P 500’s gains of 10.1% and 16.3%, respectively, in the same time frame.

Two major developments of NRXS in recent months include the announcement of its promising second-quarter 2026 results and the expansion of medical policy coverage for Percutaneous Electrical Nerve Field Stimulation, or PENFS (both in August).

In the second quarter, the company reported higher revenues and improved gross margins, mainly driven by stronger IB-Stim volumes and better reimbursement. NeurAxis’ operations are focused on developing and commercializing neuromodulation therapies, with IB-Stim as its primary product. Sales benefited from broader insurance coverage following the Category I CPT (Current Procedural Terminology) code, while the revenue mix improved as more devices were sold under full reimbursement coverage.

Management highlighted continued progress in commercial execution and payer coverage expansion. NRXS is focusing on regions with stronger insurance coverage and physician engagement to support greater PENFS utilization. The company also secured access to the Veterans Affairs (VA) health system, received additional FDA clearance for IB-Stim in functional dyspepsia (FD) and continued clinical research for additional indications.

NRXS’ One-Year Price Comparison

Image Source: Zacks Investment Research

Over the past year, the stock’s performance has remained strong, outperforming its peers like Tempus AI, Inc. TEM and Doximity, Inc. DOCS. Tempus AI and Doximity’s shares have lost 28.5% and 63.4%, respectively, in the same time frame.

Despite broader risks from its dependence on insurance coverage and regulatory requirements for additional indications, the favorable share price movement suggests NeurAxis is well-positioned to sustain its positive momentum at present.

NeurAxis is a medical technology company focused on neuromodulation therapies. Its primary product, IB-Stim, treats functional abdominal pain associated with irritable bowel syndrome (IBS) and FD, while the RED (Rectal Expulsion Device) is used to evaluate chronic constipation and pelvic floor dysfunction. NRXS primarily targets children’s hospitals while expanding into adult gastroenterology and pain practices.

NRXS' Reimbursement and Commercial Execution

The Category I CPT code has strengthened the reimbursement framework for PENFS and helped NeurAxis broaden written medical policy coverage. Recent policy additions have expanded patient access, while management has also reported progress with large commercial payers that do not yet provide coverage. Greater reimbursement visibility is important because providers are more willing to establish consistent PENFS programs when coverage spans a meaningful portion of their patient base.

NeurAxis is increasingly directing commercial resources toward markets where reimbursement is already established rather than pursuing broad geographic expansion. The company is strengthening sales coverage, clinical education, prior-authorization support and engagement with hospital administrators to improve utilization within existing accounts. This more focused model is designed to convert coverage into recurring treatment volumes while improving execution at facilities that already have physician interest and patient demand.

The Federal Supply Schedule contract provides NeurAxis with direct access to the VA system, creating a second commercial platform alongside pediatric hospitals. Early ordering and reordering activity from VA facilities has encouraged the company to expand dedicated sales coverage. Importantly, this channel is less dependent on traditional commercial insurance policy development, giving NRXS another route to build IB-Stim adoption.

Neuraxis’ Product and Clinical Positioning

FDA clearance for IB-Stim in FD and related nausea expands the product beyond its earlier IBS-focused positioning. This widens the eligible patient population and gives NeurAxis another clinically supported indication around which it can build physician awareness and utilization.

IB-Stim benefits from guideline recognition, established clinical evidence and continued research across additional pediatric and adult conditions. This evidence base strengthens discussions with physicians and payers, while studies in post-concussion syndrome, cyclic vomiting, post-operative pain and fibromyalgia provide potential avenues for future product expansion without overlapping with the currently cleared indications.

Challenges Ahead of NRXS

NRXS faces two key challenges. First, payer coverage is still incomplete, limiting the pace at which hospitals can fully activate PENFS programs. Several Medicaid fee schedules also require implementation updates, making coverage expansion and reimbursement confidence critical to broader utilization. Second, NeurAxis continues to incur losses and consume cash in operations, while planned commercialization and clinical development require meaningful working capital. This leaves NRXS dependent on sustained revenue growth and continued access to financing as it works toward profitability.

Neuraxis Stock’s Valuation

NRXS' trailing 12-month EV/Sales of 11.9X is higher than both the industry’s average of 5.3X and its two-year median of 7.7X.

Image Source: Zacks Investment Research

Tempus AI and Doximity’s trailing 12-month EV/Sales currently stand at 7.3X and 6.1X, respectively, in the same time frame.

Our Final Take on NRXS

NeurAxis’ strong share-price momentum appears to have a fundamental foundation, supported by expanding payer coverage, improved reimbursement access and increasingly focused commercial execution. The Category I CPT code is helping broaden access to PENFS, while NRXS is concentrating resources in markets where insurance coverage and physician engagement are strongest. The VA channel, expanded FDA clearance for IB-Stim and supportive clinical guidelines provide additional avenues for growth.

However, sustaining the rally will require consistent execution. Insurance coverage remains incomplete, which can limit the pace at which providers establish and expand PENFS programs. NeurAxis also continues to incur losses and requires meaningful working capital to support commercialization and clinical development, making continued progress toward a more self-sustaining operating model important.

From a valuation standpoint, NRXS appears relatively expensive following its strong appreciation, with the stock trading at a premium to both the broader industry and its own recent historical level. This suggests that investors are already pricing in meaningful progress from payer expansion, increasing IB-Stim adoption and broader commercialization opportunities. Consequently, further upside will increasingly depend on NeurAxis converting these growth drivers into sustained revenue expansion and improved operating performance.

For existing shareholders, expanding reimbursement, stronger commercial execution and a widening market opportunity support staying invested. Prospective investors may also find NRXS worth considering, although the magnitude of the recent rally and its elevated valuation warrant some caution. The momentum has scope to continue, but maintaining it will require NeurAxis to translate improving access, broader indications and new commercial channels into consistent financial progress.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research